Over the past 30 years, photodynamic therapy (PDT) has shown great development. In the clinical setting the few approved molecules belong almost exclusively to the porphyrin family; but in the scientific field, in recent years many researchers have been interested in other families of photosensitizers, among which BODIPY has shown particular interest. BODIPY is the acronym for 4,4-difluoro-4-bora-3a, 4a-diaza-s-indacene, and is a family of molecules well-known for their properties in the field of imaging. In order for these molecules to be used in PDT, a structural modification is necessary which involves the introduction of heavy atoms, such as bromine and iodine, in the beta positions of the pyrrole ring; this change favors the intersystem crossing, and increases the O-1(2) yield. This mini review focused on a series of structural changes made to BODIPYs to further increase O-1(2) production and bioavailability by improving cell targeting or photoactivity efficiency.

BODIPYs in PDT: A Journey through the Most Interesting Molecules Produced in the Last 10 Years

Malacarne, Miryam Chiara;Gariboldi, Marzia Bruna;Caruso, Enrico
2022-01-01

Abstract

Over the past 30 years, photodynamic therapy (PDT) has shown great development. In the clinical setting the few approved molecules belong almost exclusively to the porphyrin family; but in the scientific field, in recent years many researchers have been interested in other families of photosensitizers, among which BODIPY has shown particular interest. BODIPY is the acronym for 4,4-difluoro-4-bora-3a, 4a-diaza-s-indacene, and is a family of molecules well-known for their properties in the field of imaging. In order for these molecules to be used in PDT, a structural modification is necessary which involves the introduction of heavy atoms, such as bromine and iodine, in the beta positions of the pyrrole ring; this change favors the intersystem crossing, and increases the O-1(2) yield. This mini review focused on a series of structural changes made to BODIPYs to further increase O-1(2) production and bioavailability by improving cell targeting or photoactivity efficiency.
2022
2022
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene; BODIPY; photodynamic therapy; photosensitizer; Boron Compounds; Fluorescent Dyes; Triazenes; Photochemotherapy
Malacarne, Miryam Chiara; Gariboldi, Marzia Bruna; Caruso, Enrico
File in questo prodotto:
File Dimensione Formato  
ijms-23-10198 - versione pubblicata.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 6.31 MB
Formato Adobe PDF
6.31 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2140451
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 23
social impact